Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-gD-ds-PBD
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-gD-ds-PBD is an antibody-drug conjugate (ADC) primarily utilized as a non-binding negative control in preclinical oncology research, particularly in studies conducted by Genentech. It consists of a monoclonal antibody directed against the Herpes Simplex Virus (HSV) glycoprotein D (gD)—an antigen that is not expressed on human mammalian cells—conjugated to a potent pyrrolobenzodiazepine (PBD) dimer payload. The "ds" designation refers to the disulfide-based linker used to attach the payload, which is designed to be cleaved within the reducing environment of the intracellular compartment. Because the antibody does not target any human protein, anti-gD-ds-PBD serves as a critical tool for researchers to distinguish between target-mediated therapeutic effects and non-specific toxicity resulting from the systemic release or non-specific uptake of the PBD payload.
- Other names
- anti-gD-disulfide-PBDanti-gD-PBD
02
Targets
gD (HSV-2 glycoprotein D)
Beyond the preview
Go deeper on anti-gD-ds-PBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-gD-ds-PBD.